Every material Form 8-K AGENUS INC has filed with the SEC since August 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Agenus reported third-quarter 2026 revenue of $31.5 million, up from $30.2 million a year earlier but down from $34.5 million in the second quarter. Operating income was $11.4 million, its third straight positive quarter, while net income was $2.8 million, below the $63.9 million shown for the third quarter of 2025. Cash and short-term investments rose to $86.9 million at September 30, 2026, from $18.7 million at June 30, 2026, following a July private placement.
Total revenue was $31.5 million, versus $30.2 million in Q3 2025 and $34.5 million in Q2 2026.
Operating income was $11.4 million, compared with an operating loss of $4.6 million in Q3 2025.
Net income was $2.8 million for the quarter and $41.4 million for the first nine months of 2026.
Cash, cash equivalents and short-term investments were $86.9 million, including proceeds from a July private placement of approximately $85 million upfront.
Agenus and its subsidiary Agenus West amended a loan from Ocean 1181 LLC, with the outstanding principal unchanged at $24,750,000 and maturity extended to November 30, 2029. The loan carries a 13.0% annual interest rate, and interest and a $247,500 extension fee will be paid partly in newly issued common stock, which adds potential dilution for shareholders.
Outstanding principal remains $24,750,000; maturity extended to November 30, 2029
Interest rate of 13.0% per annum through maturity; monthly interest payable one-half in cash and one-half in common stock
Extension fee of $247,500, payable one-half in cash and one-half in common stock
Agreement signed August 12, 2026; shares to be issued to the lender in exempt private transactions
Agenus approved a special, one-time performance-based stock option award to Chairman and CEO Garo H. Armen on August 10, 2026, covering 1,971,500 options with a 10-year term. The exercise price of $7.78 per share was set at Armen's request to match the price granted to other management on August 5, 2026, and it was above the August 10 closing price, so the options are not priced below the team's grants.
Award: 1,971,500 performance-based stock options with a 10-year term under the Amended and Restated 2019 Equity Incentive Plan
Exercise price: $7.78 per share, matching the August 5, 2026 management grants and above the August 10, 2026 closing price
Vesting: five equal tranches tied to the stock sustaining 3x, 4x, 5x, 6x and 8x the $7.78 measurement price for 30 consecutive days within a five-year period, with a minimum three-year service requirement
No acceleration on termination or change in control; the award is subject to the company's clawback policy
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every AGENUS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →